Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Advanced Life Sciences Gets $32M In Lethargic IPO Market

Aug. 8, 2005

By Jennifer Boggs

Advanced Life Sciences Gets $32M In Lethargic IPO Market

Aug. 8, 2005

By Jennifer Boggs

Par Dropping Advancis Deal After Amoxicillin Pulsys Miss

Aug. 5, 2005

By Jennifer Boggs

Par Dropping Advancis Deal After Amoxicillin Pulsys Miss

Aug. 5, 2005

By Jennifer Boggs

Autologous Cells Company Tengion Closes $39M Series A

Aug. 4, 2005

By Jennifer Boggs

Eximias' Thymitaq Misses In Phase III Liver Cancer Trial

Aug. 4, 2005

By Jennifer Boggs

Eximias' Thymitaq Misses In Phase III Liver Cancer Trial

Aug. 4, 2005

By Jennifer Boggs

Autologous Cells Company Tengion Closes $39M Series A

Aug. 4, 2005

By Jennifer Boggs

Alnylam's IP Portfolio Gains Traction As 'One-Stop Shop'

Aug. 3, 2005

By Jennifer Boggs

Alnylam's IP Portfolio Gains Traction As 'One-Stop Shop'

Aug. 3, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 6, 2025
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space
BioWorld
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could...
GLP-1 receptor agonists continue their global victory tour
BioWorld
2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their...
AI drives financings, approvals for APAC med-tech in 2024
BioWorld MedTech
AI pulled in major financings and approvals for Asia med-techs in 2024 as Asia Pacific countries played to individual strengths to maximize AI’s applications in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.